Opko Health Inc. (OPK)
OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Adam E. Logal - Senior VP & CFO Elias Adam Zerhouni - President & Vice Chairman Phillip Frost - Chairman & CEO Yvonne Briggs - LHA Investor Relations Conference Call Participants Edward Andrew Tenthoff - Piper Sandler & Co., Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.01 per share a year ago.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H. C. Wainwright & Co., LLC Jeffrey Cohen - Ladenburg Thalmann Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw and Company Michael Petusky - Barrington Research Operator Good afternoon, and welcome to the OPKO Health First Quarter 2025 Financial Results Conference Call.
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago.
Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround
OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.
OPKO and Entera partner to develop obesity pill
OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
